Overview of Glp 1 Receptor Agonists Present Promise In Treating Substance Use

The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists ( GLP -1RAs), present an encouraging approach to treating alcohol and other substance use disorders.

A scientific evaluate reveals that GLP-1 receptor agonists might assist scale back sure substance use problems, however findings are inconsistent because of research variability and affected person variations.
Key Details About Glp 1 Receptor Agonists Present Promise In Treating Substance Use

Emerging evidence suggests that GLP-1 medications can also activate areas of the brain involved in reward, motivation, and impulse control—the same systems affected by substance use and addiction. This overlap of neurocircuitry has sparked growing interest in using GLP-1 receptor agonists to reduce urges to use alcohol and drugs and improve recovery outcomes.
Research suggests the drugs have potential for prevention and harm reduction in substance use disorders, writes Ziyad Al-Aly People taking glucagon-like peptide-1 ( GLP-1 ) receptor agonists often describe a quieting of "food noise"—persistent thoughts about food and eating that can dominate the mental space of people with obesity. Now comes a more provocative possibility: these drugs may ...

The potential role of GLP
Abstract Background: Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists ( GLP -1RAs), originally developed for type 2 diabetes and obesity, have recently gained attention for their potential effects on addictive ...
This systematic review of clinical trials focusing on glucagon-like peptide-1 receptor agonists ( GLP -1RAs) for the treatment of substance use disorders (SUDs) has several important findings.
IUPHAR review
In this review, we summarize and discuss the wealth of available evidence from testing GLP-1 receptor ( GLP -1R) agonist medications in preclinical models and humans with ASUDs, possible mechanisms underlying the impact of GLP -1R agonists on alcohol/ substance use , gaps in knowledge, and future directions.
Objectives To investigate whether initiation of glucagon-like peptide-1 ( GLP-1 ) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders (SUDs) in people with no history of SUDs (protocol 1 ) and with reduced risk of SUD related adverse clinical outcomes among people with a pre-existing SUD (protocol 2 ...

Key Details About Glp 1 Receptor Agonists Present Promise In Treating Substance Use
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists , originally developed for type 2 diabetes and obesity, have recently attracted interest as potential modulators of addictive behavior. This narrative review summarizes current knowledge on the neurobiological basis, randomized controlled trials, and psychiatric relevance of GLP-1 analogs in substance use disorders. English-language articles ...






2. Neurobiological mechanisms by which glucagon-like peptide-1 receptor agonists influence addiction To the best of our knowledge, SUDs are characterized by a dysregulation in dopaminergic signaling within the mesolimbic reward system, leading to compulsive drug use despite negative consequences. GLP -1RAs are an innovative class of antidiabetic agents that have also shown great effectiveness ...